domperidone has been researched along with Gastroparesis in 38 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Gastroparesis: Chronic delayed gastric emptying. Gastroparesis may be caused by motor dysfunction or paralysis of STOMACH muscles or may be associated with other systemic diseases such as DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The evidence confirms concerns of cardiovascular, extrapyramidal, and endocrine AEs in patients with gastroparesis treated with domperidone and metoclopramide." | 9.41 | Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis. ( Bennett, D; Betts, M; Fahrbach, K; Huh, SY; Junqueira, DR; Neupane, B, 2023) |
| "In children with insulin-dependent diabetes mellitus complicated by dyspeptic symptoms and gastroparesis, domperidone is superior to cisapride in reversing gastric emptying delay and gastric electrical abnormalities, as well as in improving dyspeptic symptoms and diabetic metabolic control." | 9.10 | Domperidone is more effective than cisapride in children with diabetic gastroparesis. ( Borrelli, O; Corrado, G; Cucchiara, S; Di Nardo, G; Dito, L; Franzese, A; Grandinetti, AL; Rea, P, 2002) |
| "Domperidone and metoclopramide were equally effective in alleviating symptoms of diabetic gastroparesis." | 9.09 | A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. ( Abell, T; Barnett, J; Koch, K; Patterson, D; Rothstein, R, 1999) |
| "To describe the health-related quality of life (HRQOL) of patients with insulin-treated diabetes and symptoms of diabetic gastroparesis and to assess the impact of domperidone on HRQOL in these patients." | 9.08 | Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. ( Farup, CE; Helbers, L; Leidy, NK; Murray, M; Quigley, EM; Williams, GR, 1998) |
| "Overall, our assessment is that there is level 3 evidence for the efficacy of domperidone in diabetic gastroparesis, leading to a grade C recommendation for its use in this condition." | 8.84 | A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. ( Pasricha, PJ; Singh, A; Sugumar, A, 2008) |
| "Prucalopride has been used in adults with gastroparesis, accelerating gastric emptying." | 8.12 | A case report of prucalopride treatment in pediatric gastroparesis: a novel therapy. ( Escobar-Serna, DP; Peralta-Palmezano, FJ; Peralta-Palmezano, JJ, 2022) |
| "The use of domperidone (DOM) for gastroparesis (GP) remains controversial and limited." | 8.12 | Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. ( Abell, T; Farrugia, G; Grover, M; Hamilton, FA; Koch, KL; Kuo, B; McCallum, RW; Miriel, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Shulman, RJ; Tonascia, J; Van Natta, M; Wilson, L; Yamada, G; Yates, KP, 2022) |
| "Domperidone improves symptoms of gastroparesis, reducing overall gastroparesis symptom severity and decreasing early satiety, postprandial fullness, and nausea." | 7.88 | Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary. ( Heckert, J; Parkman, HP, 2018) |
| "There is increased awareness about risks and benefits of using domperidone to treat gastroparesis." | 7.83 | Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. ( Midani, D; Parkman, HP; Parupalli, R; Roberts, AC; Saadi, M; Schey, R, 2016) |
| "Domperidone is a prokinetic agent used to treat gastroparesis." | 7.79 | Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS. ( Argikar, UA; Nagar, S; Parkman, HP; Pathikonda, M; Youssef, AS, 2013) |
| "The aim of this study was to identify SNPs that are associated with clinical efficacy and side effects of domperidone treatment for gastroparesis from DNA microarray experiments." | 7.78 | DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis. ( Jacobs, MR; Krynetskiy, E; Mishra, AK; Obradovic, Z; Parkman, HP; Wang, D, 2012) |
| "Domperidone is a useful alternative to metoclopramide for treatment of gastroparesis due to better tolerability." | 7.77 | Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. ( Gaughan, JP; Hurdle, JA; Jacobs, MR; Krynetskiy, E; Mishra, A; Parkman, HP; Sachdeva, P, 2011) |
| "Our aim was to determine whether domperidone could improve the symptoms of patients with gastroparesis, accelerate gastric emptying, and enhance quality of life." | 7.69 | The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. ( McCallum, RW; Sarosiek, I; Soykan, I, 1997) |
| "Domperidone is an effective antiemetic used worldwide, but there have been reports of possible cardiotoxicity." | 5.72 | Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms. ( Bustamante-Bernal, M; Espino, K; Gajendran, M; Gonzalez, Z; McCallum, R; Sarosiek, I; Siddiqui, T; Waterhouse, N; Woods, K, 2022) |
| "The evidence confirms concerns of cardiovascular, extrapyramidal, and endocrine AEs in patients with gastroparesis treated with domperidone and metoclopramide." | 5.41 | Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis. ( Bennett, D; Betts, M; Fahrbach, K; Huh, SY; Junqueira, DR; Neupane, B, 2023) |
| "In children with insulin-dependent diabetes mellitus complicated by dyspeptic symptoms and gastroparesis, domperidone is superior to cisapride in reversing gastric emptying delay and gastric electrical abnormalities, as well as in improving dyspeptic symptoms and diabetic metabolic control." | 5.10 | Domperidone is more effective than cisapride in children with diabetic gastroparesis. ( Borrelli, O; Corrado, G; Cucchiara, S; Di Nardo, G; Dito, L; Franzese, A; Grandinetti, AL; Rea, P, 2002) |
| "Domperidone and metoclopramide were equally effective in alleviating symptoms of diabetic gastroparesis." | 5.09 | A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. ( Abell, T; Barnett, J; Koch, K; Patterson, D; Rothstein, R, 1999) |
| "To describe the health-related quality of life (HRQOL) of patients with insulin-treated diabetes and symptoms of diabetic gastroparesis and to assess the impact of domperidone on HRQOL in these patients." | 5.08 | Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. ( Farup, CE; Helbers, L; Leidy, NK; Murray, M; Quigley, EM; Williams, GR, 1998) |
| "Overall, our assessment is that there is level 3 evidence for the efficacy of domperidone in diabetic gastroparesis, leading to a grade C recommendation for its use in this condition." | 4.84 | A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. ( Pasricha, PJ; Singh, A; Sugumar, A, 2008) |
| "A PubMed search was performed using search terms including gastroparesis, gastric retention, gastric emptying, accommodation, manometry, prokinetics, antiemetics, metoclopramide, domperidone, erythromycin, botulinum toxin, gastric pacing." | 4.84 | Review article: The diagnosis and management of gastroparesis. ( Haans, JJ; Masclee, AA, 2007) |
| "To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis." | 4.80 | Domperidone: a peripherally acting dopamine2-receptor antagonist. ( Barone, JA, 1999) |
| "For the drug treatment of gastroparesis, domperidone, metoclopramide and cisapride may be prescribed as prokinetics." | 4.80 | [Treatment of severely delayed gastric emptying]. ( Gooszen, HG; Samsom, M, 2000) |
| "The use of domperidone (DOM) for gastroparesis (GP) remains controversial and limited." | 4.12 | Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. ( Abell, T; Farrugia, G; Grover, M; Hamilton, FA; Koch, KL; Kuo, B; McCallum, RW; Miriel, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Shulman, RJ; Tonascia, J; Van Natta, M; Wilson, L; Yamada, G; Yates, KP, 2022) |
| "Prucalopride has been used in adults with gastroparesis, accelerating gastric emptying." | 4.12 | A case report of prucalopride treatment in pediatric gastroparesis: a novel therapy. ( Escobar-Serna, DP; Peralta-Palmezano, FJ; Peralta-Palmezano, JJ, 2022) |
| "Domperidone is a dopamine receptor antagonist used for the treatment of gastroparesis." | 3.91 | Effect of Chronic Domperidone Use on QT Interval: A Large Single Center Study. ( Bhuta, R; Cooper, J; Field, J; Malik, Z; Parkman, HP; Schey, R; Wasilewski, M, 2019) |
| "Domperidone improves symptoms of gastroparesis, reducing overall gastroparesis symptom severity and decreasing early satiety, postprandial fullness, and nausea." | 3.88 | Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary. ( Heckert, J; Parkman, HP, 2018) |
| "Domperidone, a peripheral D2 dopamine receptor antagonist, has efficacy for treatment of nausea, dyspepsia, and gastroparesis." | 3.85 | Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database. ( Alexoff, A; Ehrenpreis, ED; Roginsky, G; Smith, DG, 2017) |
| "There is increased awareness about risks and benefits of using domperidone to treat gastroparesis." | 3.83 | Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. ( Midani, D; Parkman, HP; Parupalli, R; Roberts, AC; Saadi, M; Schey, R, 2016) |
| "We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events." | 3.79 | The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. ( Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013) |
| "Domperidone is a prokinetic agent used to treat gastroparesis." | 3.79 | Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS. ( Argikar, UA; Nagar, S; Parkman, HP; Pathikonda, M; Youssef, AS, 2013) |
| "The aim of this study was to identify SNPs that are associated with clinical efficacy and side effects of domperidone treatment for gastroparesis from DNA microarray experiments." | 3.78 | DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis. ( Jacobs, MR; Krynetskiy, E; Mishra, AK; Obradovic, Z; Parkman, HP; Wang, D, 2012) |
| "Domperidone is a useful alternative to metoclopramide for treatment of gastroparesis due to better tolerability." | 3.77 | Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. ( Gaughan, JP; Hurdle, JA; Jacobs, MR; Krynetskiy, E; Mishra, A; Parkman, HP; Sachdeva, P, 2011) |
| "Our aim was to determine whether domperidone could improve the symptoms of patients with gastroparesis, accelerate gastric emptying, and enhance quality of life." | 3.69 | The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. ( McCallum, RW; Sarosiek, I; Soykan, I, 1997) |
| "Gastroparesis is a chronic motility disorder that leads to delayed gastric emptying and negatively impacts morbidity, mortality, and quality of life." | 2.49 | Gastroparesis: what is the current state-of-the-art for evaluation and medical management? What are the results? ( Lee, A, 2013) |
| "During childhood, gastroparesis is quite rare, and is mostly seen in preterm infants, with either immaturity of the gastrointestinal tract, or when allergic to cow's milk protein." | 2.42 | Current pharmacological treatment of gastroparesis. ( Hauser, B; Salvatore, S; Vandenplas, Y, 2004) |
| "Domperidone is an effective antiemetic used worldwide, but there have been reports of possible cardiotoxicity." | 1.72 | Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms. ( Bustamante-Bernal, M; Espino, K; Gajendran, M; Gonzalez, Z; McCallum, R; Sarosiek, I; Siddiqui, T; Waterhouse, N; Woods, K, 2022) |
| "Fatigue is an important significant symptom in patients with gastroparesis with a high prevalence and severity." | 1.38 | Fatigue: a prevalent symptom in gastroparesis. ( Cherian, D; Paladugu, S; Parkman, HP; Pathikonda, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (13.16) | 18.2507 |
| 2000's | 12 (31.58) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 4 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Woods, K | 1 |
| Gajendran, M | 1 |
| Gonzalez, Z | 1 |
| Bustamante-Bernal, M | 1 |
| Sarosiek, I | 3 |
| Espino, K | 1 |
| Waterhouse, N | 1 |
| Siddiqui, T | 1 |
| McCallum, R | 1 |
| Escobar-Serna, DP | 1 |
| Peralta-Palmezano, FJ | 1 |
| Peralta-Palmezano, JJ | 1 |
| Junqueira, DR | 1 |
| Bennett, D | 1 |
| Huh, SY | 1 |
| Fahrbach, K | 1 |
| Neupane, B | 1 |
| Betts, M | 1 |
| Asha, MZ | 1 |
| Khalil, SFH | 1 |
| Van Natta, M | 1 |
| Parkman, HP | 8 |
| Abell, T | 2 |
| Koch, KL | 1 |
| Kuo, B | 1 |
| Shulman, RJ | 1 |
| Farrugia, G | 1 |
| Grover, M | 1 |
| Hamilton, FA | 1 |
| Pasricha, PJ | 2 |
| Yates, KP | 1 |
| Miriel, L | 1 |
| Wilson, L | 1 |
| Yamada, G | 1 |
| Tonascia, J | 1 |
| McCallum, RW | 2 |
| Heckert, J | 1 |
| Kim, KH | 1 |
| Lee, MS | 1 |
| Choi, TY | 1 |
| Kim, TH | 1 |
| Vijayvargiya, P | 1 |
| Camilleri, M | 1 |
| Chedid, V | 1 |
| Mandawat, A | 1 |
| Erwin, PJ | 1 |
| Murad, MH | 1 |
| Field, J | 1 |
| Wasilewski, M | 1 |
| Bhuta, R | 1 |
| Malik, Z | 1 |
| Cooper, J | 1 |
| Schey, R | 2 |
| Youssef, AS | 1 |
| Argikar, UA | 1 |
| Pathikonda, M | 2 |
| Nagar, S | 1 |
| Ehrenpreis, ED | 2 |
| Deepak, P | 1 |
| Sifuentes, H | 1 |
| Devi, R | 1 |
| Du, H | 1 |
| Leikin, JB | 1 |
| Lee, A | 1 |
| Janssen, P | 1 |
| Harris, MS | 1 |
| Jones, M | 1 |
| Masaoka, T | 1 |
| Farré, R | 1 |
| Törnblom, H | 1 |
| Van Oudenhove, L | 1 |
| Simrén, M | 1 |
| Tack, J | 1 |
| Roginsky, G | 1 |
| Alexoff, A | 1 |
| Smith, DG | 1 |
| Saadi, M | 1 |
| Midani, D | 1 |
| Roberts, AC | 1 |
| Parupalli, R | 1 |
| Heimrich, KG | 1 |
| Gühne, F | 1 |
| Schulz, S | 1 |
| Mutschke, S | 1 |
| Stallmach, A | 1 |
| Rüddel, J | 1 |
| Sugumar, A | 1 |
| Singh, A | 1 |
| Stiefelhagen, P | 1 |
| Jacobs, MR | 2 |
| Mishra, A | 1 |
| Hurdle, JA | 1 |
| Sachdeva, P | 1 |
| Gaughan, JP | 1 |
| Krynetskiy, E | 2 |
| Wang, D | 1 |
| Mishra, AK | 1 |
| Obradovic, Z | 1 |
| Cherian, D | 1 |
| Paladugu, S | 1 |
| Segula, D | 1 |
| Mwandiambira, V | 1 |
| Howson, W | 1 |
| Allain, TJ | 1 |
| Vandenplas, Y | 1 |
| Hauser, B | 1 |
| Salvatore, S | 1 |
| Wang, L | 1 |
| Xie, W | 1 |
| Xing, D | 1 |
| Zhao, Y | 1 |
| Su, H | 1 |
| Meng, Z | 1 |
| Chen, Y | 1 |
| Du, L | 1 |
| Kong, MF | 1 |
| Horowitz, M | 2 |
| Jiang, RQ | 1 |
| Zhang, DX | 1 |
| Bai, CY | 1 |
| Wollheim, FA | 1 |
| Akesson, A | 1 |
| Haans, JJ | 1 |
| Masclee, AA | 1 |
| Jia, B | 1 |
| Soykan, I | 1 |
| Farup, CE | 1 |
| Leidy, NK | 1 |
| Murray, M | 1 |
| Williams, GR | 1 |
| Helbers, L | 1 |
| Quigley, EM | 1 |
| Patterson, D | 1 |
| Rothstein, R | 1 |
| Koch, K | 1 |
| Barnett, J | 1 |
| Barone, JA | 1 |
| Dumitrascu, DL | 1 |
| Weinbeck, M | 1 |
| Samsom, M | 2 |
| Gooszen, HG | 1 |
| O'Donovan, D | 1 |
| Jones, KL | 1 |
| Feinle, C | 1 |
| Rayner, CK | 1 |
| Franzese, A | 1 |
| Borrelli, O | 1 |
| Corrado, G | 1 |
| Rea, P | 1 |
| Di Nardo, G | 1 |
| Grandinetti, AL | 1 |
| Dito, L | 1 |
| Cucchiara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia[NCT05846802] | 250 participants (Anticipated) | Observational | 2024-02-28 | Not yet recruiting | |||
| Gastroparesis Registry[NCT00398801] | 591 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients[NCT01696747] | 506 participants (Actual) | Observational | 2012-07-31 | Completed | |||
| A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.[NCT02130622] | Phase 2 | 3 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Lack of recruitment) | ||
| An Investigational New Drug Program for the Use of Domperidone in the Treatment of Refractory Gastroesophageal Reflux Disease and Other Gastrointestinal Motility Disorders[NCT00777439] | 75 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| Oral Domperidone for Relief of Gastrointestinal Disorders in Patients Who Failed Standard Therapy[NCT00761254] | 42 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to PI withdrew due to increased responsibilities in clinical department.) | |||
| Impact of Preoperative Oral Carbohydrate on Recovery in Diabetic Patients After Gastrointestinal Surgery: a Pilot Randomized Controlled Trial[NCT03204344] | 65 participants (Actual) | Interventional | 2017-08-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for domperidone and Gastroparesis
| Article | Year |
|---|---|
Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis.
Topics: Adult; Child; Domperidone; Dopamine Antagonists; Gastroparesis; Humans; Metoclopramide | 2023 |
Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials.
Topics: Antiemetics; Cisapride; Diabetes Complications; Domperidone; Gastric Emptying; Gastrointestinal Agen | 2019 |
Acupuncture for symptomatic gastroparesis.
Topics: Acupuncture Therapy; Benzamides; Cimetidine; Cisapride; Diabetes Complications; Domperidone; Gastroi | 2018 |
Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.
Topics: Breath Tests; Cisapride; Domperidone; Dopamine D2 Receptor Antagonists; Dyspepsia; Gastric Emptying; | 2019 |
Gastroparesis: what is the current state-of-the-art for evaluation and medical management? What are the results?
Topics: Botulinum Toxins; Combined Modality Therapy; Diet Therapy; Domperidone; Erythromycin; Gastrointestin | 2013 |
The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis.
Topics: Cisapride; Diabetes Mellitus, Type 2; Domperidone; Erythromycin; Gastric Emptying; Gastrointestinal | 2013 |
A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis.
Topics: Clinical Trials as Topic; Diabetes Complications; Domperidone; Gastroparesis; Humans; Treatment Outc | 2008 |
Current pharmacological treatment of gastroparesis.
Topics: Adult; Child; Cisapride; Domperidone; Erythromycin; Gastrointestinal Agents; Gastroparesis; Humans; | 2004 |
Review article: The diagnosis and management of gastroparesis.
Topics: Diet; Domperidone; Dopamine Antagonists; Erythromycin; Gastric Emptying; Gastrointestinal Agents; Ga | 2007 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
[Treatment of severely delayed gastric emptying].
Topics: Cisapride; Diagnosis, Differential; Digestive System Surgical Procedures; Domperidone; Dyspepsia; El | 2000 |
Gastric emptying in diabetes: clinical significance and treatment.
Topics: Blood Glucose; Cisapride; Diabetes Mellitus; Diabetic Neuropathies; Domperidone; Gastric Emptying; G | 2002 |
6 trials available for domperidone and Gastroparesis
| Article | Year |
|---|---|
Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis.
Topics: Acupuncture Therapy; Adult; Aged; Combined Modality Therapy; Diabetes Mellitus, Type 2; Domperidone; | 2004 |
[Clinical study on Tangweikang in treating diabetic gastroparesis].
Topics: Aged; Antiemetics; Diabetes Complications; Domperidone; Drug Therapy, Combination; Drugs, Chinese He | 2007 |
Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis.
Topics: Adult; Aged; Antiemetics; Diabetes Complications; Diabetes Mellitus; Domperidone; Double-Blind Metho | 1998 |
A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis.
Topics: Adult; Aged; Antiemetics; Diabetes Mellitus, Type 1; Domperidone; Dopamine Antagonists; Double-Blind | 1999 |
Domperidone versus metoclopramide in the treatment of diabetic gastroparesis.
Topics: Adult; Aged; Diabetes Complications; Domperidone; Double-Blind Method; Female; Gastric Emptying; Gas | 2000 |
Domperidone is more effective than cisapride in children with diabetic gastroparesis.
Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Cisapride; Diabetes Mellitus, Type 1; Dom | 2002 |
20 other studies available for domperidone and Gastroparesis
| Article | Year |
|---|---|
Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms.
Topics: Domperidone; Female; Gastroparesis; Humans; Long QT Syndrome; Male; Middle Aged; Retrospective Studi | 2022 |
A case report of prucalopride treatment in pediatric gastroparesis: a novel therapy.
Topics: Adult; Benzofurans; Child; Domperidone; Gastric Emptying; Gastroparesis; Humans; Male | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.
Topics: Cohort Studies; Domperidone; Gastric Emptying; Gastroparesis; Humans; National Institute of Diabetes | 2022 |
Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary.
Topics: Adult; Antiemetics; Diabetes Complications; Domperidone; Female; Gastric Emptying; Gastroparesis; Hu | 2018 |
Effect of Chronic Domperidone Use on QT Interval: A Large Single Center Study.
Topics: Adult; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Electrocardiography; Fem | 2019 |
Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS.
Topics: Adult; Aged; Chromatography, Liquid; Domperidone; Female; Gastroparesis; Humans; Male; Middle Aged; | 2013 |
The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits.
Topics: Adverse Drug Reaction Reporting Systems; Domperidone; Dopamine Antagonists; Drug Labeling; Gastropar | 2013 |
Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antiemetics; Domperidone; D | 2017 |
Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort.
Topics: Adult; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Diarrhea; Domperidone; Dopamine An | 2016 |
[Gastroparesis in Noonan syndrome].
Topics: Adult; Antiemetics; Combined Modality Therapy; Diagnosis, Differential; Diet Therapy; Domperidone; F | 2017 |
[Prescriptions for gastroparesis].
Topics: Antiemetics; Diabetes Complications; Diagnosis, Differential; Domperidone; Gastroparesis; Humans; Ma | 2010 |
Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.
Topics: Adult; Antiemetics; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, | 2011 |
DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis.
Topics: Adult; Domperidone; Gastroparesis; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Pol | 2012 |
Fatigue: a prevalent symptom in gastroparesis.
Topics: Adult; Diagnostic Self Evaluation; Domperidone; Dopamine Antagonists; Dyspepsia; Fatigue; Female; Ga | 2012 |
Case report--the 46 year old man with a 5 month history of vomiting.
Topics: Antiemetics; Diabetes Mellitus, Type 2; Diagnosis, Differential; Domperidone; Gastroparesis; Humans; | 2011 |
A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Domperidone; Dopamine Antagonists; D | 2005 |
Diabetic gastroparesis.
Topics: Adult; Antiemetics; Diabetes Complications; Diet; Domperidone; Dopamine Agonists; Erythromycin; Fema | 2005 |
Management of intestinal involvement in systemic sclerosis.
Topics: Domperidone; Dopamine Antagonists; Gastrointestinal Agents; Gastroparesis; Humans; Indoles; Metoclop | 2007 |
[Drug therapy of gastrointestinal motility disorders].
Topics: Cisapride; Domperidone; Dyspepsia; Gastroesophageal Reflux; Gastroparesis; Humans; Metoclopramide; P | 1995 |
The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis.
Topics: Abdominal Pain; Administration, Oral; Adult; Aged; Antiemetics; Domperidone; Dopamine Antagonists; E | 1997 |